C3orf70 Inhibitors
The selected compounds represent a diverse array of inhibitors that target specific biochemical pathways, ultimately leading to the diminished functional activity of C3orf70. Rapamycin, by inhibiting mTOR, a central regulator of cell growth and protein synthesis, can decrease the overall protein levels, indirectly leading to reduced levels of C3orf70. LY 294002 and PD 98059 act on the PI3K-Akt and MEK-ERK pathways, respectively, both of which are critical for cell survival and proliferation. Their action results in the downregulation of pathways that could stabilize or activate C3orf70. Similarly, SB 203580's inhibition of p38 MAPK may suppress C3orf70 activity by affecting the stress response and cytokine production. Energy metabolism inhibitors like BIX 02189 and 2-Deoxy-D-glucose can limit energy supply, potentially restraining C3orf70's energy-dependent functions. Bortezomib, through proteasome inhibition, induces ER stress which may lead to a general downregulation of proteins, including C3orf70.
Continuing with the theme of pathway inhibition, Cyclopamine's interference with the Hedgehog signaling pathway could downregulate C3orf70 if it is influenced by that pathway. U0126 and SP600125, by inhibiting MEK1/2 and JNK, respectively, affect pathways associated with cell signaling and stress response, which could diminish C3orf70's activity if it participates in these pathways. Triptolide's broad effect on gene transcription has the potential to decrease C3orf70 expression by inhibiting transcription factors that regulate its gene. Lastly, Alsterpaullone targets cyclin-dependent kinases, which could lead to cell cycle arrest or altered transcription, thereby reducing the stability or activity of C3orf70. Collectively, these inhibitors target multiple pathways that, upon inhibition, are likely to reduce the activity of C3orf70 by either decreasing its expression, stability, or the signaling pathways that activate it.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
A specific mTOR inhibitor, Rapamycin binds FKBP12 and then inhibits the mTORC1 complex. As mTOR is a key signaling node downstream of many growth factors and upstream of protein synthesis machinery, its inhibition can lead to a decrease in overall protein synthesis, thereby diminishing the functional levels of C3orf70. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, LY 294002 blocks phosphatidylinositol 3-kinase pathways, resulting in the inhibition of the Akt signaling pathway. Since Akt can regulate a variety of cellular processes including metabolism, cell proliferation, and cell survival, the inhibition of this pathway can indirectly lead to reduced C3orf70 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A specific MEK inhibitor, PD 98059 interferes with the MEK1/2 activation and MAPK/ERK pathway. Through the inhibition of this pathway, the chemical could diminish the phosphorylation levels of downstream effectors that may be involved in the stabilization or activation of C3orf70. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor, SB 203580 selectively inhibits p38α and p38β. The p38 MAPK pathway is implicated in stress responses and cytokine production. Inhibition of this pathway can lead to a decrease in the activation of transcription factors that may regulate C3orf70 expression or activity. | ||||||
BIX 02189 | 1094614-85-3 | sc-364436 sc-364436A | 5 mg 10 mg | $224.00 $386.00 | 5 | |
A glucose transporter 1 (GLUT1) inhibitor, BIX 02189 can reduce glucose uptake, leading to decreased glycolytic flux and energy production. This reduction in energy availability can indirectly diminish the functional capacity of proteins like C3orf70 that may be energy-dependent. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor, Bortezomib can lead to the accumulation of misfolded proteins, triggering ER stress and potentially leading to the downregulation of proteins involved in cell cycle regulation and survival, including indirect effects on C3orf70 if it is part of these processes. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
A glycolysis inhibitor, 2-Deoxy-D-glucose mimics glucose but cannot be fully metabolized, which leads to the inhibition of ATP production and a decrease in cellular energy levels. This may indirectly inhibit proteins like C3orf70 that are reliant on ATP for their function. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
A Hedgehog signaling pathway inhibitor, Cyclopamine binds to and inhibits Smoothened, a G protein-coupled receptor. If C3orf70 is part of the cellular processes regulated by this pathway, its activity could be diminished due to the disruption of downstream signaling events. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
An inhibitor of MEK1/2, U0126 prevents the activation of the MAPK/ERK pathway. This inhibition may result in the diminished activity of proteins that rely on this signaling route for their function, possibly including C3orf70 if it is functionally connected to this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor, SP600125 blocks the c-Jun N-terminal kinase pathway, which is involved in cellular stress and apoptosis. The inhibition of this pathway can indirectly lead to a reduction in the functional activity of C3orf70, should it be implicated in the same cellular responses. | ||||||